Back icon Back
Freenome

Freenome

Company

By Sriparna Roy
Feb 15 (Reuters) – Blood test developer Freenome said on Thursday it has raised $254 million in a new funding round led by Swiss drugmaker Roche, to develop tests that can potentially detect multiple early-stage cancers. The company did not disclose the valuation at which the funds were raised.

https://www.reuters.com/business/healthcare-pharmaceuticals/cancer-test-firm-freenome-raises-254-mln-fresh-funding-2024-02-15/

Date

Feb 15, 2024

Category

healthcare

Lead investor

Country Icon Roche Venture Fund

Stage

Series E

Size

$254M

Explore similar Investments to Freenome

Company
Size
Date
Lead Investor
Press
Rillet

Rillet

Company
$25M
May 28, 2025
Investor Sequoia
Source
Metronome

Metronome

Company
$50M
Feb 25, 2025
Investor NEA
Source
Exa

Exa

Company
$17M
Jul 16, 2024
Investor Lightspeed
Source
Metronome

Metronome

Company
$43M
Jan 31, 2024
Investor NEA
Source
Meter

Meter

Company
$170M
Jun 12, 2025
Investor General Catalyst
Source
Lumafield

Lumafield

Company
$75M
Mar 13, 2025
Investor IVP
Source
Raycast

Raycast

Company
$30M
Sep 25, 2024
Investor Atomico
Source
Orb

Orb

Company
$25M
Sep 17, 2024
Investor Greylock
Source
Sanity

Sanity

Company
$85M
May 12, 2025
Investor Bullhound Capital
Source
Mynt

Mynt

Company
$23M
Dec 11, 2024
Investor Incore
Source
Roadway

Roadway

Company
$3.2M
Aug 6, 2025
Investor Precursor Ventures
Source
Butlr

Butlr

Company
$38M
Aug 26, 2024
Investor Foundry
Source

Startups, venture funds
& everything in between.

Explore verified companies, top VCs, and practical guides built to help you raise, invest, and grow faster.
Made by Omnius. For builders, by builders.
Venture Funds Startups Investments Events Programs Case Studies Interviews & Lectures Reports & Publications